Patients with HL treated with the AIEOP LH-2004 protocol (2014-2017)

Excluded from the study:
-no biological samples available for genotyping
-incomplete clinical/hematological/biochemical data
-refused consent

N= 133 patients with HL

TG criteria and treatment

Treatment Groups (TG)	LH2004 protocol
TG1	3× ABVD +:
IA, IIA supradiaphragmatic no bulky no bulky, no pulmonary hilum, <4 lymphatic sites, or IA, IIA infradiaphragmatic < 4 lymphatic sites	CR: stop others: RT 25.2 Gy IF
TG2	4× COPP/ABV +:
patients not included in groups 1 or 3	CR: RT 14.4 Gy IF PR: 2× IEP + RT 25.2 Gy IF
TG3	4× COPP/ABV +:
IIIB, IV; M/T ≥ 0.33 all stages	CR: 2× COPP/ABV + RT 14.4 Gy IF PR: 2× IEP + RT 25.2 Gy IF
If RP ≤ 50% after 2° Cycle of chemotherapy : TG1: IEP/OPPA/COPP/IEP + RT; TG2 & TG3: IEP/OPPA/IEP/OPPA/IEP + RT	
ABVD	**IEP**
Doxorubicin: 25 mg/m^2 IV days 1	Ifosfamide: 2000 mg/m^2 IV days 1–5
Bleomycin: 10 mg/m^2 IV days 1 & 15	Etoposide: 120 mg/m^2 IV days 1–5
Vinblastine: 6 mg/m^2 IV days 1 &.15	Prednisone: 100 mg/m^2 orally days 1–5
DTIC: 375 mg/m^2 IV days 1 & 15	**COPP/ABV**
OPPA	Cyclophosphamide: 600 mg/m2 IV day 1
Vincristine: 1.5 mg/m^2 IV days 1& 8 & 15	Vincristine: 1.4 mg/m2 IV day 1
Procarbazine: 100 mg/m^2 orally days 1–14	Prednisone: 40 mg/m2 orally days 1–14
Prednisone: 60 mg/m^2 IV days 1–14	Procarbazine: 100 mg/m2 orally days 1–7
Doxorubicin: 40 mg/m^2 IV days 1&15	Doxorubicin: 35 mg/m2 IV day 8
	Bleomycin: 10 mg/m2 IV day 8
	Vinblastine: 6 mg/m2 IV day 8

ROC curves analysis to identify the best hematological /biochemical variable associated with relapse or disease progression

+

+

HLA-G SNP+3027 evaluation

multivariate COX regression analysis for FFP

Construction of the FPR model

FPR prediction model in patients with NScHL (n=108)

Comparison of the TG and the FPR prediction models for FFP and OS

Assessment of the prediction for treatment response between FPR and PET/CT scan